Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,251.65INR
2:42pm IST
Change (% chg)

Rs-111.65 (-3.32%)
Prev Close
Rs3,363.30
Open
Rs3,370.00
Day's High
Rs3,372.85
Day's Low
Rs3,201.00
Volume
508,432
Avg. Vol
344,475
52-wk High
Rs3,666.25
52-wk Low
Rs2,246.50

REDY.NS

Chart for REDY.NS

About

Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active... (more)

Overall

Beta: 0.32
Market Cap(Mil.): Rs573,038.12
Shares Outstanding(Mil.): 170.38
Dividend: 18.00
Yield (%): 0.54

Financials

  REDY.NS Industry Sector
P/E (TTM): 163.52 39.93 40.74
EPS (TTM): 20.57 -- --
ROI: -- 18.93 18.19
ROE: -- 19.71 19.08
Search Stocks

BUZZ-India's Dr Reddy's falls; Credit Suisse cuts to "neutral"

** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse

11:04am IST

BUZZ-India's Dr.Reddy's falls; Health Canada quarantines products from Srikakulam plant

** Dr.Reddy's Laboratories shares fall 1.2 pct ** Canadian importers agree to quarantine products from Dr.Reddy's Srikakulam plant and Ipca Laboratories' Pithampur facility, Health Canada says (http://bit.ly/1HyUTK4) ** Quarantine request due to data integrity concerns, Canadian drug regulator adds ** Continued concerns that sales in Russia may be impacted due to brewing financial crisis in the region also weigh (Reuters Messaging: abhishek.vishnoi.thomsonreuters.com@reuters.net)

24 Dec 2014

Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

Shares of India's Dr Reddy's Laboratories gain 0.9 percent.

05 Nov 2014

MARKET EYE-India's Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (indulal.p@thomsonreuters.com/indulal.p.thomsonreuters.com@reut ers.net)

05 Nov 2014

Dr.Reddy's rises; filing shows U.S. market share gains

Reuters Market Eye - Shares in Dr.Reddy's Laboratories gain 1.58 percent vs a 0.02 percent fall in the Nifty.

20 Aug 2014

MARKET EYE -India's Dr.Reddy's rises; filing shows U.S. market share gains

* Shares in India's Dr.Reddy's Laboratories gain 1.1 percent vs a 0.2 percent fall in the NSE index. * A filing with the U.S. Securities and Exchange Commission on Monday shows market share gains in key drugs in the U.S. market, analysts say. (http://1.usa.gov/1tk9u78) (abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)

20 Aug 2014

Earnings vs. Estimates

Search Stocks